Sodium-glucose cotransporter 2 (SGLT2)

Where the papers sit

12 papers from the last 6 months study Sodium-glucose cotransporter 2 (SGLT2) directly · updated from PubMed 12 Oct 2026

• Renal Protection in Diabetes

  Renal protection is being linked to suppression of glucotoxic stress, tubular senescence, and oxidative injury rather than filtration changes alone. Dapagliflozin engages an SLC5A2-SRC-ERK/STAT3 network in proximal tubules, while CTRP1-mediated pathways emerge as potential targets. Human and experimental work also tracks metabolic, vascular, and inflammatory kidney markers. Sex-specific responses remain an open consideration in early cardiorenal disease.

  4 papers · 33.3%

• Cardiorenal Outcomes in Diabetes

  SGLT2 inhibitor use is moving toward routine cardiorenal risk reduction and more individualized prescribing in type 2 diabetes. Real-world and target-trial analyses focus on incident chronic kidney disease and comparative cardiovascular outcomes between agents. Primary-care underuse remains a practical barrier despite accumulating outcome evidence. Ketone-body metabolism is being explored as a precision-medicine marker in ischemic heart failure, but its predictive value remains unresolved.

  4 papers · 33.3%

• Systemic Effects Beyond Glycemia

  SGLT2 research here examines effects beyond glucose lowering, including combination therapy, blood pressure, coronary flow, appetite, body weight, and ischemic brain injury. Dapagliflozin appears compatible with add-on regimens and may improve vascular measures in selected patients with type 2 diabetes and liver steatosis. Clinical and rodent evidence suggests little consistent effect on appetite or weight. Cerebral protection remains preliminary, with evidence limited to a rat ischemia-reperfusion model.

  4 papers · 33.3%